Intel stock extends gains after report of possible U.S. government stake
RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech company with a market capitalization of $4.84 million, announced Tuesday that its PL-14 Allergy Blocker demonstrated over 60% deposition in the nasal vestibule during preclinical testing, according to a company press release. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt.
The study, conducted in collaboration with the University of Parma in Italy, used a validated silicone-based human nasal cast and fluorescein-labeled imaging to assess the spray deposition profile of PL-14 under clinically relevant conditions. While the company shows promise in its research, InvestingPro data reveals it is not yet profitable, with an EBITDA of -$1.18 million in the last twelve months.
The nasal vestibule is the first physiological region exposed to airborne allergens, making it a critical target area for the company’s Capture & Contain (C&C) platform technology, which aims to form a protective barrier against allergens.
"We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward," said Tomer Izraeli, CEO of Polyrizon.
The evaluation was led by Professor Fabio Sonvico from the University of Parma’s Department of Food and Drug, who also serves on Polyrizon’s Scientific Advisory Board.
The hydrogel formulation maintained favorable sprayability and coverage under standard administration angles, demonstrating potential for self-administration, according to the company.
Polyrizon’s technology is designed to form a thin hydrogel-based shield in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.
The company plans to continue preclinical validation and advance toward clinical trials as part of the development path for the C&C platform.
The global allergen blocker market was valued at $0.14 billion in 2024 and is expected to reach $0.21 billion by 2033, according to Business Research Insights cited in the release. With a current ratio of 10.16, Polyrizon maintains strong liquidity to fund its development programs. Discover more financial insights and 10 additional ProTips for PLRZ on InvestingPro.
In other recent news, Polyrizon Ltd. has successfully secured its listing on the Nasdaq Capital Market following a hearing with the Nasdaq Hearings Panel. This decision comes after concerns were raised regarding the company’s securities issuance, which had led to potential delisting due to shareholder dilution. Additionally, Polyrizon reported promising preclinical results for its hydrogel-based Trap & Target platform for intranasal drug delivery, conducted in collaboration with the University of Parma. The study showed significant targeted deposition in the nasal cavity, which is favorable for nose-to-brain transport.
In another development, Polyrizon has initiated preclinical studies for an intranasal delivery system of Benzodiazepines to treat acute repetitive seizures and status epilepticus. This research is also in collaboration with Professor Fabio Sonvico from the University of Parma. Meanwhile, board member Omer Srugo has resigned, though the company confirmed that this was not due to any disagreements. The board has affirmed that four of its members are independent, as per Nasdaq’s listing rules. These recent developments highlight Polyrizon’s ongoing efforts in advancing its medical technologies and maintaining its regulatory compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.